Current Open ResearchTrials
BOPP – Beta-blockers Or Placebo for Primary Prophylaxis of Oesophageal Varices. A blinded, UK multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial.
Re-opened 05/07/2021
Planned Recruitment end date: September 2022
ESSENCE – The Effect of Semaglutide in Non-cirrhotic, Non-alcoholic Steatohepatitis.
Site opened: 31/03/2021
Planned recruitment end date: 23/06/2023
MADRIGAL – A Phase 3, Multinational, Double-Blind, Randomised, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients with Non-alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation.
Site opened: 15/10/2019
Planned recruitment end date: 15/10/2019
MICAH – Multicentre Cohort Study in Alcoholic Hepatitis (in-patient trial)
Site opened: 30/09/2020
Planned recruitment end date: 30/11/2021
MIRAGE - Pilot Randomised Trial of Functional Imagery Training Plus Treatment as Usual Versus Treatment As Usual Alone To Reduce Alcohol-Related Harm in Patients With Alcohol-Related Liver Disease Admitted To Hospital
Site opened: 19/04/2021
Planned recruitment end date: 30/09/2022
Pro Euro DILI – Prospective European DILI registry: Creation of a multicentre and Multidisciplinary European Registry of Prospective Drug-induced Liver Injury Cases
Site opened: 05/09/2017
Planned recruitment end date: 01/04/2022
TAK-242 – a Randomised, Double-blind, Placebo-controlled, Multicentre, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety Pharmacokinetics and Pharmacodynamics of Intravenous TAK-242 in Subjects With Acute Alcoholic Hepatitis Causing Decompensation of Alcohol-related Cirrhosis and Acute-on-Chronic Liver Failure
Site opened: 09/11/2020
Planned recruitment end date: 05/02/2022
UK-PBC – Investigation of the Genetic and Molecular Pathogenesis of Primary Biliary Cirrhosis Registry.
Site opened: 09/07/2008
Planned recruitment end date: 31/08/2021
UK-PSC – A UK Collaborative Study to Determine the Genetic Basis of Primary Sclerosing Cholangitis.
Site opened: 04/03/2009
Planned recruitment end date: 01/07/2023
GENFIT ELATIVE – A Double-blind, Randomized, Placebo-controlled Study and Open-Label Long Term Extension To Evaluate the Efficacy and Safety of Elafibranor 80mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Site opened: 13/08/2021
Planned recruitment end date: tbc
CYMABAY ASSURE – An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Site opened: 23/09/2021
Planned recruitment end date: 30/11/2022
SPRING – A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis
Site opened: 19/10/2021
Planned recruitment end date: tbc